Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Uveal Melanoma 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Immunoblastic Lymphadenopathy 1Graft vs Host Disease 1

Interventions

pembrolizumab 9Nivolumab 4tislelizumab 2spartalizumab 2budigalimab 2atezolizumab 2Ipilimumab 2venetoclax 1ruxolitinib 1rovalpituzumab tesirine 1poly ICLC 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1avelumab 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1LY2940680 1Injections 1Immunotherapy, Adoptive 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × ruxolitinib × Dermatologic × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡